JF
BPMC

Jump Financial’s Blueprint Medicines BPMC Stock Holding History

Jump Financial’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-147,325
Closed -$18.9M – 1799
2025
Q2 		$18.9M Buy
+147,325
New +$15.3M 0.21% 107
2024
Q4 		– Sell
-12,704
Closed -$1.18M – 1664
2024
Q3 		$1.18M Buy
+12,704
New +$1.26M 0.02% 725
2023
Q4 		– Sell
-4,367
Closed -$219K – 1813
2023
Q3 		$219K Buy
+4,367
New +$233K 0.01% 1465
2023
Q1 		– Sell
-39,525
Closed -$1.73M – 1614
2022
Q4 		$1.73M Buy
+39,525
New +$1.9M 0.09% 303
2022
Q3 		– Sell
-58,370
Closed -$2.95M – 1607
2022
Q2 		$2.95M Buy
58,370
+45,619
+358% +$2.67M 0.13% 219
2022
Q1 		$814K Buy
+12,751
New +$915K 0.03% 606

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Jump Financial's BPMC Position: Q3 2025 in Review

Jump Financial sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 147,325 shares — an estimated $18.9M sold.

Jump Financial first reported a position in BPMC in Q1 2022 and held it in 6 quarters. The position peaked at $18.9M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Jump Financial reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Jump Financial sold 147,325 Blueprint Medicines shares in Q3 2025, an estimated $18.9M.
  • Jump Financial first reported a position in Blueprint Medicines in Q1 2022 and held it in 6 quarters.
  • Jump Financial's Blueprint Medicines position peaked at $18.9M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Jump Financial's 13F filing for Q3 2025, filed 13 Nov 2025.